Middle East Pharmaceutical Industries Company SJSC

The company maintains a strong liquidity position, with a current ratio of 3.13, indicating that it has more than three times the current assets to cover its short-term liabilities. However, its liquidity risk is assessed as medium, primarily due to a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.15 suggests a conservative capital structure, with limited leverage relative to equity. Free cash flow of SAR 35.6 million provides flexibility for reinvestment or shareholder returns, though capital expenditures of SAR 34.4 million indicate ongoing investment in operations. Profitability metrics show a return on equity of 23.31% and a return on assets of 16.18%, both exceeding the typical thresholds for the pharmaceutical industry, which often prioritizes long-term R&D over immediate returns. Operating income of SAR 108.4 million and a gross profit of SAR 286.8 million reflect strong cost control and pricing power, though the company's net income of SAR 97.0 million is slightly lower, likely due to interest and tax expenses. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond the Middle East. This concentration increases exposure to regional economic and regulatory shifts, particularly in Saudi Arabia, where the company is headquartered. No material revenue is attributed to international markets, and no segment-specific financials are provided in the latest filing. Growth trajectory is not explicitly outlined in the latest financials, but the company's operating cash flow of SAR 88.5 million and free cash flow of SAR 35.6 million suggest capacity for reinvestment or expansion. No specific guidance is provided for the next fiscal year, and the absence of analyst estimates beyond a single "hold" recommendation indicates limited visibility into near-term performance. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No recent equity issuance or ATM/shelf registration is disclosed, and the company has not issued new shares in the past year. The conservative debt structure and strong cash flow mitigate credit risk, though the company's reliance on a single geographic market increases exposure to local economic volatility. No recent filings or transcripts are available to provide insight into management commentary or strategic direction. The company's latest financials do not include material events or disclosures beyond standard operating results.